These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 32926749)

  • 1. Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors.
    Terrault NA; Burton J; Ghobrial M; Verna E; Bayer J; Klein C; Victor D; Mohan S; Trotter J; Dodge J; Niemann CU; Rubin RA
    Hepatology; 2021 Jun; 73(6):2110-2123. PubMed ID: 32926749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients.
    Friebus-Kardash J; Gäckler A; Kribben A; Witzke O; Wedemeyer H; Treckmann J; Herzer K; Eisenberger U
    Transpl Infect Dis; 2019 Oct; 21(5):e13146. PubMed ID: 31306562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients.
    Woolley AE; Singh SK; Goldberg HJ; Mallidi HR; Givertz MM; Mehra MR; Coppolino A; Kusztos AE; Johnson ME; Chen K; Haddad EA; Fanikos J; Harrington DP; Camp PC; Baden LR;
    N Engl J Med; 2019 Apr; 380(17):1606-1617. PubMed ID: 30946553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection.
    Sise ME; Goldberg DS; Kort JJ; Schaubel DE; Alloway RR; Durand CM; Fontana RJ; Brown RS; Friedewald JJ; Prenner S; Landis JR; Fernando M; Phillips CC; Woodle ES; Rike-Shields A; Sherman KE; Elias N; Williams WW; Gustafson JL; Desai NM; Barnaba B; Norman SP; Doshi M; Sultan ST; Aull MJ; Levitsky J; Belshe DS; Chung RT; Reese PP
    J Am Soc Nephrol; 2020 Nov; 31(11):2678-2687. PubMed ID: 32843477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C Virus NAT-Positive Solid Organ Allografts Transplanted Into Hepatitis C Virus-Negative Recipients: A Real-World Experience.
    Kapila N; Menon KVN; Al-Khalloufi K; Vanatta JM; Murgas C; Reino D; Ebaid S; Shaw JJ; Agrawal N; Rhazouani S; Navas V; Sheffield C; Rahman AU; Castillo M; Lindenmeyer CC; Miller C; Quintini C; Zervos XB
    Hepatology; 2020 Jul; 72(1):32-41. PubMed ID: 31659775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes following liver transplantation from HCV-seropositive donors to HCV-seronegative recipients.
    Aqel B; Wijarnpreecha K; Pungpapong S; Taner CB; Reddy K; Leise M; Mi L; Dickson RC
    J Hepatol; 2021 Apr; 74(4):873-880. PubMed ID: 33188903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients.
    Agarwal K; Castells L; Müllhaupt B; Rosenberg WMC; McNabb B; Arterburn S; Camus G; McNally J; Stamm LM; Brainard DM; Mani Subramanian G; Mariño Z; Dufour JF; Forns X
    J Hepatol; 2018 Sep; 69(3):603-607. PubMed ID: 29886154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver, simultaneous liver-kidney, and kidney transplantation from hepatitis C-positive donors in hepatitis C-negative recipients: A single-center study.
    Crismale JF; Khalid M; Bhansali A; De Boccardo G; Khaim R; Florman SS; Shapiro R; Schiano TD
    Clin Transplant; 2020 Jan; 34(1):e13761. PubMed ID: 31808193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial.
    Cypel M; Feld JJ; Galasso M; Pinto Ribeiro RV; Marks N; Kuczynski M; Kumar D; Bahinskaya I; Bagnato VS; Kurachi C; Slutsky AS; Yeung JC; Donahoe L; de Perrot M; Yasufuku K; Pierre A; Binnie M; Chaparro C; Martinu T; Chen M; Tikkanen J; Chow CW; Sidhu A; Waddell TK; Keshavjee S; Singer LG; Humar A
    Lancet Respir Med; 2020 Feb; 8(2):192-201. PubMed ID: 31606437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)-Viremic Donors Into HCV-Negative Recipients: Outcomes Following Liver Transplant of HCV-Viremic Donors.
    Cotter TG; Paul S; Sandıkçı B; Couri T; Bodzin AS; Little EC; Sundaram V; Charlton M
    Hepatology; 2019 Jun; 69(6):2381-2395. PubMed ID: 30706517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study.
    Feld JJ; Cypel M; Kumar D; Dahari H; Pinto Ribeiro RV; Marks N; Kamkar N; Bahinskaya I; Onofrio FQ; Zahoor MA; Cerrochi O; Tinckam K; Kim SJ; Schiff J; Reichman TW; McDonald M; Alba C; Waddell TK; Sapisochin G; Selzner M; Keshavjee S; Janssen HLA; Hansen BE; Singer LG; Humar A
    Lancet Gastroenterol Hepatol; 2020 Jul; 5(7):649-657. PubMed ID: 32389183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of hepatitis C viremic donors for liver transplant recipients without hepatitis C. A veterans transplant center report.
    Said A; Weiss M; Varhelyi A; Farago R; Ballweg C; Rice J; Agarwal P; Fernandez L; Foley D
    Transpl Infect Dis; 2021 Apr; 23(2):e13466. PubMed ID: 32931616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors.
    Kwong AJ; Wall A; Melcher M; Wang U; Ahmed A; Subramanian A; Kwo PY
    Am J Transplant; 2019 May; 19(5):1380-1387. PubMed ID: 30378723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient.
    Campos-Varela I; Agudelo EZ; Sarkar M; Roberts JP; Terrault NA
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29125670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Center-level trends in utilization of HCV-exposed donors for HCV-uninfected kidney and liver transplant recipients in the United States.
    Bowring MG; Shaffer AA; Massie AB; Cameron A; Desai N; Sulkowski M; Garonzik-Wang J; Segev DL
    Am J Transplant; 2019 Aug; 19(8):2329-2341. PubMed ID: 30861279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of kidney, liver, and simultaneous liver and kidney transplants from hepatitis c infected donors to hepatitis c naïve recipients: A large single center experience.
    Elbeshbeshy H; Modi N; Patel T; Matthews I; Kampert T; Lee J; Okeke R; Caliskan Y; Fleetwood V; Varma C; Gabris B; Bastani B; Abu Al Rub F; Guenette A; Befeler A; Agbim U; Desai R; Alsabbagh E; Qureshi K; Schnitzler M; Lentine KL; Randall HB; Nazzal M
    Clin Transplant; 2024 Jan; 38(1):e15161. PubMed ID: 37842872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of HCV Viremic Kidneys with Genotyping/Subtyping-Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China.
    Zhang H; Liu Q; Hu S; Zhong M; Peng F; Guo Y; Fang C; Nie M; Tan L; Dai H; Xie X; Peng L; Lan G
    Biomed Res Int; 2022; 2022():3758744. PubMed ID: 35941983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes.
    Axelrod DA; Schnitzler MA; Alhamad T; Gordon F; Bloom RD; Hess GP; Xiao H; Nazzal M; Segev DL; Dharnidharka VR; Naik AS; Lam NN; Ouseph R; Kasiske BL; Durand CM; Lentine KL
    Am J Transplant; 2018 Oct; 18(10):2473-2482. PubMed ID: 29701909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of allograft HCV recurrence with peri-transplant human monoclonal antibody MBL-HCV1 combined with a single oral direct-acting antiviral: A proof-of-concept study.
    Smith HL; Chung RT; Mantry P; Chapman W; Curry MP; Schiano TD; Boucher E; Cheslock P; Wang Y; Molrine DC
    J Viral Hepat; 2017 Mar; 24(3):197-206. PubMed ID: 28127942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens.
    Shah AP; Cameron A; Singh P; Frank AM; Fenkel JM
    Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28060446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.